Daewoong Bio, “Big pharmas control selecting comparison drugs”

Published: 2017-12-15 16:33:11

Updated: 2017-12-15 16:33:11

Daewoong Bio(CEO Byung-Gook Yang) announced on the 13^th that the company filed an administrative trial to the Central Administrative Appeals Commission, which claimed ‘Cancellation of Choline Alfoscerate Comparison Drug Selection and Designation of Gliatamin Comparison Drugs’.

The Ministry of Food and Drug Safety(MFDS) previously selected ‘CKD Gliatilin Tab’ as a ‘choline alfoscerate’ comparis...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.